Actively Recruiting
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2026-02-12
212
Participants Needed
4
Research Sites
147 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire de Saint Etienne
Lead Sponsor
D
Diagnostica Stago
Collaborating Sponsor
AI-Summary
What this Trial Is About
Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of bleeding in the first 6 months. Most of the guidelines propose to integrate the bleeding risk in the choice of therapies. Thrombin generation assay (TGA) reflects an overall hemostatic response and could be a useful biomarker. Proven on the thrombotic side in the CAT population, useful in the assessment of the bleeding risk of hemophiliac patients, the TGA is emerging as a tool. The investigators to measure TGA in cancer patients included prospectively, having recently developed a CAT and to evaluate the association between the measurement and the risk of hemorrhagic complication under anticoagulant during the first 6 month of treatment.
CONDITIONS
Official Title
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with active cancer, as defined by current French recommendations (Mahé I et al Rev Mal Respir 2021)
- Presenting acute proximal deep vein thrombosis of the lower limb (DVT) and/or proximal pulmonary embolism (at least segmental) (PE), confirmed by objective tests (Doppler ultrasound in the event of DVT; lung scintigraphy or CT scan in the event of PE)
- No contraindication for anticoagulant treatment at a curative dose at the time of inclusion
You will not qualify if you...
- Patients participating in a therapeutic clinical trial with a blinded therapy or an open-label therapeutic trial who are included in the experimental treatment group.
- Patients already on anticoagulant at a curative dose for valvular or rhythmic embolic disease or a history of venous thromboembolic disease
- Hematological malignancies
- Patients with a contraindication to anticoagulant treatment on inclusion
- Patient whose relay by DOAC has already been carried out.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Chu Clermont-Ferrand
Clermont-Ferrand, France, 63003
Not Yet Recruiting
2
CHU de Grenoble
Grenoble, France, 38043
Not Yet Recruiting
3
HCL
Lyon, France
Not Yet Recruiting
4
Chu St-Etienne
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
G
Géraldine POENOU, MD PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here